Avelo, a Schlieren-based start-up, has just closed its oversubscribed seed financing round of CHF 2.2 Mio. to accelerate the clinical validation of their breath collector in order to make a difference in the fight against Tuberculosis and other respiratory infections. The company focus on primary care breath test for infectious lung diseases. The round was led by OCCIDENT with participation from Privilège Ventures, Sanner Ventures, Zürcher Kantonalbank and several business angels.
Wenger Vieli has advised Avelo. The team included Michael Baier (partner, venture capital / m&a, pictured) and Dominique Mattmann (associate, venture capital / m&a) from the Wenger Vieli Start-up Desk.